Program
Betamethasone
Also written as “Ropivacaine + Clonidine + Betamethasone”, “Fixed Dose Etoricoxib + Betamethasone” and “calcipotriol and betamethasone (LEO 80185 gel)”.
Its studies are mostly in Psoriasis · Bursitis · Hip Fractures · Rhinitis, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| LEO Pharma | 30 open or running | phase 3since Jan 17, 2006 | Jan 17, 2006 | none ahead |
| Abbott | 10 open or running | phase 3since Dec 12, 2007 | Dec 12, 2007 | none ahead |
| Cartiva | 10 open or running | phase 2since Feb 17, 2014 | Feb 17, 2014 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 10 open or running | phase 3since Dec 28, 2025 | Dec 28, 2025 | none ahead |
| Merck | 10 open or running | phase 4since Aug 20, 2009 | Aug 20, 2009 | none ahead |
| Tolmar | 10 open or running | phase 1since Apr 6, 2017 | Apr 6, 2017 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2006First study: phase 3 study in PsoriasisNew to LEO PharmaLEO Pharma · NCT00279162 · 160 enrolled · United States
- Dec 12, 2007Abbott's first study: phase 3 study in PsoriasisNew to AbbottAbbott · NCT00574249 · 730 enrolled · Austria, Belgium, Czech Republic and more
- Apr 29, 2008Phase 3 study in Psoriasis VulgarisLEO Pharma · NCT00670241 · 458 enrolled · Canada
- Aug 20, 2009Merck's first study: phase 4 study in RhinitisNew to MerckMerck · NCT00963573 · 100 enrolled
- Aug 25, 2010Phase 3 study in Psoriasis VulgarisLEO Pharma · NCT01188928 · 1,152 enrolled · United States
- Feb 17, 2014Cartiva's first study: phase 2 study in Hip FracturesNew to CartivaCartiva · NCT02066844 · 40 enrolled · United States
- Apr 6, 2017Tolmar's first study: phase 1 study in Scalp PsoriasisNew to TolmarTolmar · NCT03122353 · 699 enrolled · United States
- Dec 28, 2025Laboratorios Silanes S.A. de C.V.'s first study: phase 3 study in BursitisNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT07328022 · 89 enrolled · Mexico
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| vamorolonerule | reveragen-biopharma-inc | phase 4 | 11 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07328022Bursitis · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Aug 20, 2025 | 89 |
| NCT03122353Scalp Psoriasis · United States | 1 | Completed | Tolmar | Nov 15, 2017 | 699 |
| NCT02066844Hip Fractures · United States | 2 | Completed | Cartiva | Aug 2014 | 40 |
| NCT01188928Psoriasis Vulgaris · United States | 3 | Completed | LEO Pharma | Mar 2011 | 1,152 |
| NCT00963573Rhinitis | 4 | Completed | Merck | Nov 2006 | 100 |
| NCT00670241Psoriasis Vulgaris · Canada | 3 | Completed | LEO Pharma | Feb 2009 | 458 |
| NCT00574249Psoriasis · Austria, Belgium, Czech Republic and more | 3 | Completed | Abbott | Oct 2008 | 730 |
| NCT00279162Psoriasis · United States | 3 | Completed | LEO Pharma | 160 |
How it is read
Names in the registry
- “Ropivacaine + Clonidine + Betamethasone”, 3 entries
- “Fixed Dose Etoricoxib + Betamethasone”, 1 entry
- “calcipotriol and betamethasone (LEO 80185 gel)”, 1 entry
- “Calcipotriol plus betamethasone”, 1 entry
- “Calcipotriene/betamethasone gel and ointment”, 1 entry
Conditions, from the studies’ own filings
- Psoriasis, 5 studies
- Bursitis, 1 study
- Hip Fractures, 1 study
- Rhinitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.